Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...

(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...

A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care first-time share sales since October.Most Read from BloombergManhattan’s Morning ...

A report on energy transition investments from BloombergNEF showed that global investment in clean energy technologies hit a ...

Shares in Venture Global are expected to make their debut on the New York Stock Exchange after the company raised $1.75 ...

Bond manager’s $7 billion stake in Venture Global latest sign that traditional asset managers are making inroads investing in ...

The president joined leaders from OpenAI, Oracle and SoftBank to launch the ambitious project, but questions remain about its ...

Baker Hughes has been awarded a major contract to provide a modularised liquefied natural gas (LNG) system and power island to support Venture Global (VG) LNG projects in the US.

That means Mr. Liang had a cornucopia of technical talent at his disposal, all galvanized by the challenge of doing AI ...

Semperis is an early pioneer of Identity Threat Detection and Response (ITDR), one of the fastest growing cybersecurity categories. Today, Gartner ranks ITDR a "top CISO trend" as organizations adopt ...

The company has also signed a services frame agreement to support phase 1 and 2 of the Venture Global's Plaquemines LNG ...

Taking yet another step in its preparations for its IPO, B2B marketplace unicorn OfBusiness has converted itself into a ...